Literature DB >> 11015308

Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha).

M L Cohen1, K Schenck.   

Abstract

Contractile responses to ergotamine, sumatriptan and the novel 5-HT(1F) receptor agonists, LY334370 and LY344864 were examined using the rabbit saphenous vein. Ergotamine (pEC(50)=8.7+/-0.06) was 30 fold more potent than 5-hydroxytryptamine (5-HT) (pEC(50)=7.2+/-0.13) and 300 fold more potent than sumatriptan (pEC(50)=6.0+/-0.08) in contracting the rabbit saphenous vein in vitro. The selective 5-HT(1F) receptor agonists, LY334370 or LY344864 (up to 10(-4) M), did not contract the rabbit saphenous vein. The contractile response to ergotamine in this tissue resulted from activation of both alpha(1) and 5-HT(1B/1D) receptors based on the observation that prazosin (10(-6) M), an alpha-adrenoceptor antagonist, and GR127935 (10(-8) M) a 5-HT(1B/1D) receptor antagonist, dextrally shifted the contractile response to ergotamine. In contrast, prazosin (10(-6) M) did not alter contraction to sumatriptan whereas GR127935 (10(-8) M) was a potent antagonist (-log K(B)=10.0) suggesting that sumatriptan-induced contraction of the rabbit saphenous vein was mediated only by activation of receptors similar or identical to 5-HT(1B/1D) receptors. PGF(2alpha) (3x10(-7) M) produced a modest increase (approximately 5.0 - 10.0% maximum PGF(2alpha) contraction) in saphenous vein force. Precontraction with PGF(2alpha) (3x10(-7) M) dramatically augmented the potency and maximal contractile response to sumatriptan (pEC(50)=7.1) and modestly enhanced the contractile potency of ergotamine (pEC(50)=9.0) in the rabbit saphenous vein. However, PGF(2alpha) (3x10(-7) M) only unmasked a contraction to the 5-HT(1F) receptor agonists when concentrations exceeded 10(-5) M, concentrations considerably higher than their 5-HT(1F) receptor affinities. LY334370 (10(-6) M) pretreatment did not alter contraction to either sumatriptan or ergotamine and a higher concentration (10(-5) M) of LY334370 or LY344864 inhibited contraction to sumatriptan. Thus, activation of 5-HT(1F) receptors will not induce vascular contraction (either alone or following modest tone with PGF(2alpha)) or augment contraction to other contractile agonists in the rabbit saphenous vein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015308      PMCID: PMC1572346          DOI: 10.1038/sj.bjp.0703587

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Serotonin and vasoconstrictor synergism.

Authors:  O Yildiz; J R Smith; R E Purdy
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

2.  Distinct 5-HT(1B) and 5-HT(1D) serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors.

Authors:  M W Hamblin; R W McGuffin; M A Metcalf; D M Dorsa; K M Merchant
Journal:  Mol Cell Neurosci       Date:  1992-12       Impact factor: 4.314

3.  G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines.

Authors:  D S Dupuis; F C Colpaert; P J Pauwels
Journal:  Br J Pharmacol       Date:  1998-05       Impact factor: 8.739

4.  An attempt at selective protection from phenoxybenzamine of postjunctional alpha-adrenoceptor subtypes mediating contractions to noradrenaline in the rabbit isolated saphenous vein.

Authors:  C J Daly; W R Dunn; J C McGrath; V G Wilson
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

5.  Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries.

Authors:  M L Cohen; K W Johnson; K W Schenck; L A Phebus
Journal:  Cephalalgia       Date:  1997-10       Impact factor: 6.292

Review 6.  Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?

Authors:  M R MacLean
Journal:  Trends Pharmacol Sci       Date:  1999-12       Impact factor: 14.819

7.  Amplification of responses to sumatriptan by various agonists in rabbit isolated iliac artery.

Authors:  O Yildiz; M Tuncer
Journal:  J Cardiovasc Pharmacol       Date:  1995-03       Impact factor: 3.105

8.  5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.

Authors:  K W Johnson; J M Schaus; M M Durkin; J E Audia; S W Kaldor; M E Flaugh; N Adham; J M Zgombick; M L Cohen; T A Branchek; L A Phebus
Journal:  Neuroreport       Date:  1997-07-07       Impact factor: 1.837

9.  Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm.

Authors:  H Yasue; S Omote; A Takizawa; M Nagao
Journal:  Angiology       Date:  1981-06       Impact factor: 3.619

10.  Coronary side-effect potential of current and prospective antimigraine drugs.

Authors:  A MaassenVanDenBrink; M Reekers; W A Bax; M D Ferrari; P R Saxena
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

View more
  6 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction.

Authors:  Anyue Yin; Akihiro Yamada; Wiro B Stam; Johan G C van Hasselt; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2018-07-10       Impact factor: 8.739

Review 3.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 5.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

6.  Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Authors:  Eloísa Rubio-Beltrán; Alejandro Labastida-Ramírez; Kristian A Haanes; Antoon van den Bogaerdt; Ad J J C Bogers; Eric Zanelli; Laurent Meeus; A H Jan Danser; Michael R Gralinski; Peter B Senese; Kirk W Johnson; Joseph Kovalchin; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.